Diethylcarbamazine (Dec) Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 100 mg
Reference Brands: Generic formulations available in various generic brands
Category:
Anthelmintic
Diethylcarbamazine (DEC) inhibits microfilariae and adult filarial worms, disrupting their metabolism and immune evasion. It effectively treats filariasis and tropical parasitic infections, reducing symptoms, preventing disease transmission, and supporting overall health. Benefits include parasite elimination, symptom relief, and improved quality of life in affected regions.
Diethylcarbamazine (DEC) tablet is available in Tablets
and strengths such as 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Diethylcarbamazine (DEC) tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Diethylcarbamazine (DEC) tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Diethylcarbamazine (DEC) tablets, marketed as Eletcroos and generics, are approved in the US by the FDA and in the EU via EMA for treating lymphatic filariasis and tropical parasitic infections. Regulatory approval requires dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, clinical trial and quality data review facilitate approval, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports timely approval, safe use, and global availability, aiding in parasite control and disease prevention worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing